Oxford, UK, 5 August 2019 — The Native Antigen Company, one of the world’s leading suppliers of reagents that enable research into vaccine development and diagnostics for emerging and endemic infectious diseases, today announced the release of its Rubella virus-like particles (VLPs) at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo in Anaheim, CA, USA. The Rubella VLPs are a unique product in its new range of Rubella virus reagents, adding to the Company’s extensive selection of recombinant VLPs that offer researchers a reliable source of high-quality reagents for immunoassay development and manufacturing.
Credit: The Native Antigen CompanyThe Native Antigen Company specializes in the isolation and purification of native antigens and recombinant proteins from viral and bacterial pathogens. The first-to-market Rubella VLPs are expressed as recombinant proteins in the Company’s proprietary mammalian cell expression system. Recombinant expression of the Rubella structural polyprotein in HEK293 cells enables reliable and cost-effective production of high-quality VLPs, helping to ensure researchers achieve consistent and accurate results throughout immunoassay development and scale-up manufacturing. The Native Antigen Company also offers Rubella antigens, monoclonal antibodies and ELISAs for use in a wide range of research applications.
“We are committed to expanding our product portfolio of reagents to facilitate cutting-edge vaccine and diagnostics research for infectious disease," said Dr. Andy Lane, commercial director, The Native Antigen Company. "Our reputation for delivering high-quality VLPs is growing and the addition of the Rubella VLPs to our new Rubella virus range means we are now able to offer researchers a consistent, well-defined, and cost-effective alternative to current native Rubella products on the market, which are often difficult to produce and increasingly expensive.”
Rubella virus is the causative agent of a highly contagious acute self-limiting and generally mild disease known as Rubella or German measles, predominantly affecting children and young adults. However, when contracted during the first trimester of pregnancy, Rubella poses a significant health risk to the fetus. Rubella infection and vaccination provide >95 percent* chance of developing lifetime immunity.
For more information about The Native Antigen Company’s recombinant Rubella (strain F-Therien) VLPs, consisting of spike glycoprotein E1, spike glycoprotein E2, and Capsid protein, please visit: https://thenativeantigencompany.com/products/rubella-virus-strain-f-therien-vlp-spike-glycoprotein-e1-e2/
The Native Antigen Company will be attending 71st AACC Annual Scientific Meeting & Clinical Lab Expo in Anaheim, CA, USA from 4–8 August 2019. Visit booth 4263 to find out more about its Rubella VLPs and other native and recombinant viral and bacterial antigens, antibodies and immunoassays, and bespoke product development and custom manufacturing services.
*Lambert N, Strebel P, Orenstein W, Icenogle J, Poland GA. (2015) Rubella. Lancet. Jun 6;385(9984):2297-307.
Like this article? Click here to subscribe to free newsletters from Lab Manager